Cutaneous lupus: Insights into pathogenesis and disease classification

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 200-204

  Werth, Victoria P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 2 Rhoads Pavilion ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; CYTOKINE; IMMUNOLOGIC FACTOR; INTERLEUKIN 12; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; B LYMPHOCYTE; DENDRITIC CELL; DISCOID LUPUS ERYTHEMATOSUS; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; ERYTHEMA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; NECROSIS; NONHUMAN; PATHOGENESIS; RADIATION DOSE; REVIEW; SKIN LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ANIMAL; CLASSIFICATION; GENETICS; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; B-LYMPHOCYTES; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, CUTANEOUS; NECROSIS; RISK FACTORS; T-LYMPHOCYTES;

EID: 38449109473     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus. 1997;6:96-104.
2. Peng SL, Cappadona J, McNiff JM, et al. Pathogenesis of autoimmunity in alphabeta T cell-deficient lupus-prone mice. Clin Exp Immunol. 1998;111:107-16.
3. Chan OT, Paliwal V, McNiff JM, et al. Deficiency in beta(2)- Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Fas(lpr) Mice: An Example of Disease Regulation at the Organ Level. J Immunol. 2001;167:2985-90.
4. Choi JY, Gao W, Odegard J, et al. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis Rheum. 2006;54:3277-83.
5. Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003;139:50-4.
6. Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of TNFalpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000;115:726-30.
7. Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990;87:1233-7.
8. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993;92:14-8.
9. McHugh NJ, Owen P, Cox B, et al. MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis. 2006;65:488-94.
10. Werth VP, Callen JP, Ang G, Sullivan KE. Associations of tumor necrosis factor-α (TNFα) and HLA polymorphisms with adult dermatomyositis: Implications for a unique pathogenesis. J Invest Dermatol. 2002;119:617-20.
11. Clancy RM, Backer CB, Yin X, et al. Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: Implications for pathogenesis. Arthr Rheum. 2004;50:2598-603.
12. Bowness P, Davies KA, Norsworthy PJ, et al. Hereditary C1q deficiency and systemic lupus erythematosus. QJM. 1994;87:455-64.
13. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: Complement deficiency and systemic lupus erythematosus revisited. J Immunol. 1997;158:4525-8.
14. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Gen. 2006;79:731-7.
15. Lehmann P, Holzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 1990;22:181-7.
16. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: A 15-year experience. J Am Acad Dermatol. 2001;45:86-95.
17. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus-review of 60 patients. Photochem Photobiol. 2001;73:532-6.
18. Lokitz ML, Billet S, Patel P, et al. Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: Implications for phototesting and sunblocking strategies. Photodermatol, Photoimmunol & Photomed. 2006;22:290-6.
19. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: A report of 5 cases. Arch Dermatol. 2001;137:1196-8.
20. Michet CJ Jr., McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985;60:105-13.
21. Gallego H, Crutchfield CE, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis. 1999;63:231-4.
22. LeFeber WP, Norris DA, Ryan SR, et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest. 1984;74:1545-51.
23. Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol. 1993;100 (Suppl):56-68.
24. Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus. J Clin Invest. 1992;90:1067-76.
25. Casciola-Rosen L, Rosen L. Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus. 1997;6:175-80.
26. Tan EM. Autoimmunity and apoptosis. J Exp Med. 1994;179:1083-6.
27. Reefman E, Kuiper H, Jonkman MF, et al. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology. 2006;45:538-44.
28. Kuhn A, Herrmann M, Kleber S, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2007;54:939-50.
29. Chung JH, Kwon OS, Eun HC, et al. Apoptosis in the pathogenesis of cutaneous lupus erythematosus. Am J Dermatopath. 1998;20:233-41.
30. Pablos JL, Santiago B, Galindo M, et al. Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. J Pathol. 1999;188:63-8.
31. Smith ML, Fornace AJ Jr. p53-mediated protective responses to UV irradiation. Proc Natl Acad Sci U S A. 1997;94:12255-7.
32. Brysk MM, Selvanayagam P, Arany I, et al. Induction of apoptotic nuclei by interferon-gamma and by predesquamin in cultured keratinocytes. J Interferon Cytokine Res. 1995;15:1029-35.
33. Daniels FJ. Histochemical responses of human skin following ultraviolet radiation. J Invest Dermatol. 1961;37:351-6.
34. Tron VA, Trotter MJ, Tang L, et al. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol. 1998;153:579-85.
35. Henkart PA. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity. 1994;1:343-6.
36. Wright SC, Kumar P, Tam AW, et al. . Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J Cell Biochem. 1992;48:344-55.
37. Lowin B, Hahne M, Mattmann C, et al. . Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370:650-2.
38. Norris DA, Whang K, David-Bajar K, Bennion SD. The influence of ultraviolet light on immunological cytotoxicity in the skin. Photochem Photobiol. 1997;65:636-46.
39. Nakajima M, Nakajima A, Kayagaki N, et al. Expression of Fas ligand and its receptor in cutaneous lupus: Implication in tissue injury. Clin Immunol Immunopath. 1997;83:223-9.
40. Furukawa F, Itoh T, Wakita H, et al. Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol. 1999;118:164-70.
41. O'Brien CA, Wolin SL. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5S rRNA precursors. Genes Dev. 1994;8:2891-903.
42. Xue D, Shi H, Smith JD, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A. 2003;100:7503-8.
43. Kock A, Schwarz T, Kirnbauer R, et al. Human keratinocytes are a source for tumor necrosis factor alpha: Evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med. 1990;172:1609-14.
44. Yarosh D, Both D, Kibitel J, et al. Regulation of TNFalpha production and release in human and mouse keratinocytes and mouse skin after UV-B radiation. Photodermatol Photoimmunol & Photomed. 2000;16:263-70.
45. Takashima A, Bergstresser PR. Impact of UVB radiation on the epidermal cytokine network. Photochem Photobiol. 1996;63:397-400.
46. Brink N, Scamel M, Young AR, et al. Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflam Res. 2000;49:290-6.
47. Kondo S, Sauder DN. Keratinocyte-derived cytokines and UVB-induced immunosuppression. J Dermatol. 1995;22:888-93.
48. Ono SJ, Nakamura T, Miyazaki D, et al. Chemokines: Roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol. 2005;111:1185-99.
49. Meller S, Winterberg F, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504-16.
50. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-43.
51. Wenzel J, Worenkamper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205:435-42.
52. Wenzel J, Uerlich M, Worrenkamper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153:1011-5.
53. Kita Y, Kuroda K, Mimori T, et al. T cell receptor clonotypes in skin lesions from patients with systemic lupus erythematosus. J Invest Dermatol. 1998;110:41-6.
54. Denfeld RW, Kind P, Sontheimer RD, et al. In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 1997;40:814-21.
55. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194:397-404.
56. Campbell JJ, Haraldsen G, Pan J, et al. . The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 2999;400:776-80.
57. Wenzel J, Henze S, Worenkamper E, et al. Role of chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol. 2005;124:1241-8.
58. Wenzel J, Henze S, Brahler S, et al. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol. 2005;14:454-9.
59. Kuhn A, Fehsel K, Lehmann P, et al. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. J Invest Dermatol. 1998;111:149-53.
60. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:1810-6.
61. Patel P, Werth V. Cutaneous lupus erythematosus: A review. Dermatol Clin. 2002;19:583-92.
62. Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clinics in Dermatology. 2004;22:121-4.
63. Gammon WR, Briggaman RA. Bullous SLE: A phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:S28-34.
64. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999;135:569-73.
65. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: Revised criteria for diagnosis. Br J Dermatol. 1995;132:921-8.
66. McGrath H Jr. Ultraviolet A1 (340-400 nm) irradiation and systemic lupus erythematosus. J Investig Dermatol Symp Proc. 1999;4:79-84.
67. Polderman MC, le Cessie S, Huizinga TW, Pavel S. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus. Rheumatology (Oxford). 2004;43:1402-4.
68. Werth VP, Bashir M, Zhang W. IL-12 completely blocks the secretion of TNFα from cultured skin fibroblasts and keratinocytes. J Invest Dermatol. 2003;120:116-22.
69. Schwarz A, Stander S, Berneburg M, et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nature Cell Biol. 2002;4:26-31.
70. Werth VP, Zhang W. Wavelength-specific synergy between ultraviolet radiation and interleukin-1 alpha in the regulation of matrix-related genes: Mechanistic role for tumor necrosis factor-alpha. J Invest Dermatol. 1999;113:196-201.
71. Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum. 1995;38:1152-6.